OGEN 1.25
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OGEN 1.25 (OGEN 1.25).
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting effects on reproductive tissues, bone density, and cardiovascular system.
| Metabolism | Hepatic metabolism via CYP3A4; undergoes enterohepatic recirculation; primarily excreted as conjugates in urine. |
| Excretion | Renal: 95% (as glucuronide and sulfate conjugates); biliary/fecal: ~5% |
| Half-life | Terminal elimination half-life: 10–24 hours (mean ~15 h); clinically, steady-state achieved in 5–7 days |
| Protein binding | 98–99% bound to albumin and sex hormone-binding globulin (SHBG) |
| Volume of Distribution | Vd: 1.5–2.0 L/kg; distributes widely into tissues including breast, bone, and reproductive organs |
| Bioavailability | Oral: 30–50% due to first-pass metabolism; transdermal: 100% |
| Onset of Action | Oral: 2–4 weeks for full therapeutic effect on vasomotor symptoms; estrogenic effect on vaginal epithelium detectable within 2 weeks |
| Duration of Action | Duration: 24–48 hours for single-dose effects; continuous dosing required for sustained symptom relief |
1.25 mg orally once daily for 3 weeks, followed by a 1-week rest period; cyclic therapy.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment provided; use with caution in severe renal impairment. |
| Liver impairment | No specific dose adjustment provided; use with caution in severe hepatic impairment. |
| Pediatric use | Not indicated for use in pediatric patients. |
| Geriatric use | No specific dosage adjustment; initiate at the lowest effective dose and monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OGEN 1.25 (OGEN 1.25).
| Breastfeeding | Estrogens are excreted in human breast milk. Ogen 1.25 may suppress lactation and reduce milk production. Not recommended during breastfeeding. M/P ratio for estropipate is not established. |
| Teratogenic Risk | Estropipate, an estrogen, increases risk of fetal harm, including congenital anomalies and urogenital tract abnormalities, especially with first-trimester exposure. Use is contraindicated in pregnancy. Second- and third-trimester exposure may cause feminization of male fetuses and long-term reproductive tract effects in females. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer, stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction in postmenopausal women. Increased risk of breast cancer with combined estrogen-progestin therapy.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known or suspected estrogen-dependent neoplasia (e.g., breast cancer)","Active or history of venous thromboembolism (e.g., DVT, PE)","Active or history of arterial thromboembolism (e.g., stroke, MI)","Known protein C, protein S, or antithrombin deficiency","Known or suspected pregnancy","Severe hepatic impairment or disease"]
| Precautions | ["Cardiovascular disorders: increased risk of stroke, DVT, PE, MI","Malignant neoplasms: endometrial cancer (unopposed estrogen), breast cancer (with progestin)","Gallbladder disease, hypercalcemia","Hepatic impairment, cholestatic jaundice","Hereditary angioedema, hypothyroidism, elevated triglycerides","Retinal vascular thrombosis, fluid retention","Dementia (increased risk in women ≥65 years)"] |
Loading safety data…
| Fetal Monitoring |
| Monitor for signs of thromboembolism, hypertension, and hypercalcemia. Perform regular prenatal ultrasounds to assess fetal growth and anatomy due to increased risk of anomalies. |
| Fertility Effects | Estrogen use may impair fertility by suppressing ovulation and altering endometrial receptivity. Discontinuation may resume normal menstrual cycles and fertility. |